Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | KDM4A | O75164 | 11/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25352553 | 1.00 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1KDM5AKDM4AKDM4C | |
| SCHEMBL1461562 | 0.98 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1KDM5AKDM4AKDM4C | |
| SCHEMBL735310 | 0.92 | ALDH1A1 (0.37) | L3MBTL1ALDH1A1KDM5ATSHRLMNA | |
| SCHEMBL29991123 | 0.89 | ALDH1A1 (0.41) | ALDH1A1KDM5AKDM4AKDM4CKDM7A | |
| SCHEMBL24703880 | 0.87 | ALDH1A1 (0.42) | ALDH1A1KDM5AKDM4AKDM4CKDM7A | |
| SCHEMBL735688 | 0.83 | — | — | |
| SCHEMBL22205611 | 0.83 | LMNA (0.44) | ALDH1A1KDM5AKDM4AKDM4CKDM7A | |
| SCHEMBL21645392 | 0.82 | GPR84 (0.43) | ALDH1A1KDM5AKDM4AKDM4CKDM7A | |
| SCHEMBL2304549 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM5ADNM1TSHR | |
| SCHEMBL3963400 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM5ADNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11236103-B2 | Bifunctional compounds | BIOTHERYX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | L3MBTL1 3001/4885ALDH1A1 3991/4885KDM5A 4222/4885 |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | L3MBTL1 773/4885ALDH1A1 3779/4885KDM5A 2251/4885 |
| US-11236103-B2 | Bifunctional compounds | CDK2, CDK6, CDK5 | L3MBTL1 773/4885ALDH1A1 3779/4885KDM5A 2251/4885 |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | L3MBTL1 1587/4885ALDH1A1 2964/4885KDM5A 3722/4885 |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | L3MBTL1 773/4885ALDH1A1 3779/4885KDM5A 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.